{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:51:03Z","timestamp":1790733063686,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70112697"],"award-info":[{"award-number":["70112697"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HE 5240\/5-1"],"award-info":[{"award-number":["HE 5240\/5-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HE 5240\/5-2"],"award-info":[{"award-number":["HE 5240\/5-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HE5240\/6-2"],"award-info":[{"award-number":["HE5240\/6-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["638035"],"award-info":[{"award-number":["638035"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Isolated myeloid sarcoma (MS) is a rare malignancy in which myeloid blast forms tumors at various locations while the bone marrow (BM) remains cytomorphologically free from disease. We analyzed isolated MS from four patients and their BMs at initial diagnosis and follow-up, using a custom next-generation sequencing (NGS) panel. We observed possible clonal evolution and a clonal hematopoiesis of indeterminate potential (CHIP)-like finding in the BM of one of three cases with detectable mutations. Clinical presentation of one patient suggested extramedullary confined homing of blasts to distal sites in the relapse situation still sparing the BM. In summary, our findings shall motivate future work regarding signals of extramedullary blast trafficking and clonal evolution in MS.<\/jats:p>","DOI":"10.1007\/s00277-020-04313-x","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T07:03:12Z","timestamp":1603782192000},"page":"499-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Newly diagnosed isolated myeloid sarcoma\u2013paired NGS panel analysis of extramedullary tumor and bone marrow"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3514-5686","authenticated-orcid":false,"given":"Nils W.","family":"Engel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochim","family":"Reinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora M.","family":"Borchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Panagiota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razif","family":"Gabdoulline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Thol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"issue":"4","key":"4313_CR1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000497210","volume":"42","author":"M Magdy","year":"2019","unstructured":"Magdy M, Abdel Karim N, Eldessouki I, Gaber O, Rahouma M, Ghareeb M (2019) Myeloid Sarcoma. Oncol Res Treat 42(4):224\u2013229. https:\/\/doi.org\/10.1159\/000497210","journal-title":"Oncol Res Treat"},{"issue":"12","key":"4313_CR2","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1002\/1097-0142(19861215)58:12<2697::aid-cncr2820581225>3.0.co;2-r","volume":"58","author":"JM Meis","year":"1986","unstructured":"Meis JM, Butler JJ, Osborne BM, Manning JT (1986) Granulocytic sarcoma in nonleukemic patients. Cancer 58(12):2697\u20132709. https:\/\/doi.org\/10.1002\/1097-0142(19861215)58:12<2697::aid-cncr2820581225>3.0.co;2-r","journal-title":"Cancer"},{"issue":"6","key":"4313_CR3","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/1097-0142(19810915)48:6<1426::aid-cncr2820480626>3.0.co;2-g","volume":"48","author":"RS Neiman","year":"1981","unstructured":"Neiman RS, Barcos M, Berard C, Bonner H, Mann R, Rydell RE, Bennett JM (1981) Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer 48(6):1426\u20131437. https:\/\/doi.org\/10.1002\/1097-0142(19810915)48:6<1426::aid-cncr2820480626>3.0.co;2-g","journal-title":"Cancer"},{"key":"4313_CR4","doi-asserted-by":"publisher","unstructured":"Bewersdorf JP, Shallis RM, Boddu PC, Wood B, Radich J, Halene S, Zeidan AM (2019) The minimal that kills: why defining and targeting measurable residual disease is the \u201cSine Qua Non\u201d for further progress in management of acute myeloid leukemia. Blood Rev 43:100650. https:\/\/doi.org\/10.1016\/j.blre.2019.100650","DOI":"10.1016\/j.blre.2019.100650"},{"issue":"1","key":"4313_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","volume":"126","author":"DP Steensma","year":"2015","unstructured":"Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126(1):9\u201316. https:\/\/doi.org\/10.1182\/blood-2015-03-631747","journal-title":"Blood"},{"issue":"8","key":"4313_CR6","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s00277-017-3027-5","volume":"96","author":"M Heuser","year":"2017","unstructured":"Heuser M, Gabdoulline R, Loffeld P, Dobbernack V, Kreimeyer H, Pankratz M, Flintrop M, Liebich A, Klesse S, Panagiota V, Stadler M, Wichmann M, Shahswar R, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Geffers R, Schlegelberger B, Gohring G, Kreipe HH, Germing U, Ganser A, Kroger N, Koenecke C, Thol F (2017) Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. Ann Hematol 96(8):1361\u20131372. https:\/\/doi.org\/10.1007\/s00277-017-3027-5","journal-title":"Ann Hematol"},{"issue":"16","key":"4313_CR7","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, Hambach L, Stadler M, Koenecke C, Flintrop M, Pankratz M, Wichmann M, Neziri B, Buttner K, Heida B, Klesse S, Chaturvedi A, Kloos A, Gohring G, Schlegelberger B, Gaidzik VI, Bullinger L, Fiedler W, Heim A, Hamwi I, Eder M, Krauter J, Schlenk RF, Paschka P, Dohner K, Dohner H, Ganser A, Heuser M (2018) Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood 132(16):1703\u20131713. https:\/\/doi.org\/10.1182\/blood-2018-02-829911","journal-title":"Blood"},{"issue":"22","key":"4313_CR8","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1182\/bloodadvances.2018020222","volume":"2","author":"DP Steensma","year":"2018","unstructured":"Steensma DP (2018) Clinical consequences of clonal hematopoiesis of indeterminate potential. Blood Adv 2(22):3404\u20133410. https:\/\/doi.org\/10.1182\/bloodadvances.2018020222","journal-title":"Blood Adv"},{"issue":"4","key":"4313_CR9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1080\/10428194.2016.1225208","volume":"58","author":"C Pastoret","year":"2017","unstructured":"Pastoret C, Houot R, Llamas-Gutierrez F, Boulland ML, Marchand T, Tas P, Ly-Sunnaram B, Gandemer V, Lamy T, Roussel M, Fest T (2017) Detection of clonal heterogeneity and targetable mutations in myeloid sarcoma by high-throughput sequencing. Leuk Lymphoma 58(4):1008\u20131012. https:\/\/doi.org\/10.1080\/10428194.2016.1225208","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"4313_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1182\/blood-2017-07-793620","volume":"131","author":"V Lazarevic","year":"2018","unstructured":"Lazarevic V, Orsmark-Pietras C, Lilljebjorn H, Pettersson L, Rissler M, Lubking A, Ehinger M, Juliusson G, Fioretos T (2018) Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow. Blood 131(5):577\u2013581. https:\/\/doi.org\/10.1182\/blood-2017-07-793620","journal-title":"Blood"},{"issue":"3","key":"4313_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jmoldx.2019.11.004","volume":"22","author":"B Werstein","year":"2020","unstructured":"Werstein B, Dunlap J, Cascio MJ, Ohgami RS, Fan G, Press R, Raess PW (2020) Molecular discordance between myeloid sarcomas and concurrent bone marrows occurs in actionable genes and is associated with worse overall survival. The Journal of Molecular Diagnostics 22(3):338\u2013345. https:\/\/doi.org\/10.1016\/j.jmoldx.2019.11.004","journal-title":"The Journal of Molecular Diagnostics"},{"issue":"2","key":"4313_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/pbc.22500","volume":"55","author":"CM Faaij","year":"2010","unstructured":"Faaij CM, Willemze AJ, R\u00e9v\u00e9sz T, Balzarolo M, Tensen CP, Hoogeboom M, Vermeer MH, van Wering E, Zwaan CM, Kaspers GJ, Story C, van Halteren AG, Vossen JM, Egeler RM, van Tol MJ, Annels NE (2010) Chemokine\/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: differential roles for CCR2, CCR5, CXCR4 and CXCR7. Pediatr Blood Cancer 55(2):344\u2013348. https:\/\/doi.org\/10.1002\/pbc.22500","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"4313_CR13","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1182\/blood-2018-09-875047","volume":"133","author":"JS Jutzi","year":"2019","unstructured":"Jutzi JS, Basu T, Pellmann M, Kaiser S, Steinemann D, Sanders MA, Hinai ASA, Zeilemaker A, Bojtine Kovacs S, Koellerer C, Ostendorp J, Aumann K, Wang W, Raffoux E, Cassinat B, Bullinger L, Schlegelberger B, Valk PJM, Pahl HL (2019) Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations. Blood 133(16):1766\u20131777. https:\/\/doi.org\/10.1182\/blood-2018-09-875047","journal-title":"Blood"},{"issue":"15","key":"4313_CR14","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1182\/bloodadvances.2017007922","volume":"1","author":"K Takahashi","year":"2017","unstructured":"Takahashi K, Wang F, Kantarjian H, Song X, Patel K, Neelapu S, Gumbs C, Little L, Tippen S, Thornton R, DiNardo CD, Ravandi F, Bueso-Ramos C, Zhang J, Wu X, Garcia-Manero G, Futreal PA (2017) Copy number alterations detected as clonal hematopoiesis of indeterminate potential. Blood Adv 1(15):1031\u20131036. https:\/\/doi.org\/10.1182\/bloodadvances.2017007922","journal-title":"Blood Adv"},{"issue":"2","key":"4313_CR15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/10428194.2017.1339879","volume":"59","author":"K Kashofer","year":"2018","unstructured":"Kashofer K, Gornicec M, Lind K, Caraffini V, Schauer S, Beham-Schmid C, Wolfler A, Hoefler G, Sill H, Zebisch A (2018) Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing. Leuk Lymphoma 59(2):501\u2013504. https:\/\/doi.org\/10.1080\/10428194.2017.1339879","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"4313_CR16","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/s41467-019-09374-9","volume":"10","author":"EE Heyer","year":"2019","unstructured":"Heyer EE, Deveson IW, Wooi D, Selinger CI, Lyons RJ, Hayes VM, O'Toole SA, Ballinger ML, Gill D, Thomas DM, Mercer TR, Blackburn J (2019) Diagnosis of fusion genes using targeted RNA sequencing. Nat Commun 10(1):1388. https:\/\/doi.org\/10.1038\/s41467-019-09374-9","journal-title":"Nat Commun"},{"issue":"9","key":"4313_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.leukres.2014.05.004","volume":"38","author":"MK Mirza","year":"2014","unstructured":"Mirza MK, Sukhanova M, Stolzel F, Onel K, Larson RA, Stock W, Ehninger G, Kuithan F, Zophel K, Reddy P, Joseph L, Raca G (2014) Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays. Leuk Res 38(9):1091\u20131096. https:\/\/doi.org\/10.1016\/j.leukres.2014.05.004","journal-title":"Leuk Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04313-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04313-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04313-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T23:52:57Z","timestamp":1635292377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04313-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["4313"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04313-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"27 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"F.T. reports advisory role for Abbvie, Astellas, Daiichi Sankyo, Novartis, Celgene, and Pfizer. M.H. reports Honoraria from Novartis, Pfizer and PriME Oncology, Consulting or advisory role for Abbvie, Bayer Pharma AG, Daiichi Sankyo, Novartis and Pfizer, and Research Funding to institution from Astellas, Bayer Pharma AG, BergenBio, Daiichi Sankyo, Karyopharm, Novartis, Pfizer, and Roche. W.F. reports advisory role for Amgen, Pfizer, Novartis, Jazz Pharmaceuticals, Celgene, Morphosys and Ariad\/Incyte, Research funding from Amgen, previous support for meeting attendance from Amgen, Jazz Pharmaceuticals, Daiichi Sankyo Oncology and Servier and support in medical writing from Amgen, Pfizer, and AbbVie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was waived, given the retrospective nature of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}